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In the pathogenesis of Alzheimer’s disease (AD), the
most common neurodegenerative disorder, the amyloid-
b (Ab) peptide plays a key role. Originally, the Ab fibrils
were postulated to be the neurotoxic agents for a long
time, because an increased presence of extracellular amy-
loid plaques, composed primarily of insoluble Ab fibrils,
is found in the brain of affected patients. Recent studies,
however, showed a higher cytotoxicity for small Ab oligo-
mers than for the Ab fibrils so that these soluble Ab oli-
gomers are moving to the centre of interest now [1,2].
Because of the unstable and noncrystalline nature of
these species, obtaining structural information for small
oligomers is an experimentally challenging task. Novel
structural insight was obtained from a recent crystal struc-
ture of a tetramer formed by the amyloidogenic residues
18-41 of the Ab peptide. To enhance stability, this frag-
ment was genetically engineered into the CDR3 loop
region of a shark Ig single variable domain antibody [3].
Since the respective crystal structure is stabilized by
the antibody moiety, we investigated, whether the
respective topology also represents a stable fold for the
isolated Ab-peptide.
We performed molecular dynamics simulations in expli-
cit solvent for the isolated tetrameric amyloid-b fragment
in two different lengths (17-40 and 17-42) and the derived
dimer and monomer structures. In contrast to Ab17-40,
we observed a stable dynamical behaviour for the tetramer
of Ab17-42: the extension of the antiparallel b-sheet
through the residues 41 and 42 is responsible for the
enhanced structural stability.
In summary, our results suggest that the novel tetra-
meric structure represents a stable oligomer conformation
for the longer and more neurotoxic Ab42 species and thus
could be a new target in rational drug design aiming at the
prevention of toxic oligomer formation.
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